Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Sep 05, 2021 5:38pm
152 Views
Post# 33815891

RE:RE:RE:RE:RE:RE:RE:Weekly Report Card

RE:RE:RE:RE:RE:RE:RE:Weekly Report Card

Even if they don't have a partnership lined up it would still be great if this was more focused on the business side of the equation but I expect it's going to be clinical heavy and so not much new for us. Hopefully useful for others though.


SPCEO1 wrote: It is worth recalling that I did not give much credence to that rumor. But while we have been focused on the odd timing of the KOL event because we think any partnership will take longer to put together, one possible explanation for the timing of the KOL event is that they will announce a partnership this week and then follow up with the KOL event explaining it a week from tomorrow. So, maybe our focus on the kong time it takes to put a partnership together did not take into considereation any partnership discussions that may have begun well before TH announced its intention to partner. And maybe Paul's recent call for any pharma wanting a second shot on this very big goal to pony up $50 million to get into the action was basically the last call to other pharmas who might be interested before they signed a deal with the partner they already have lined up. 
 

qwerty22 wrote:

I know SPCEO has this 60 day rumour about when a deal will happen but to me it's much, much longer than that and I tend to think we are only at the start of the process. Making these guesses about wether the process is going well or badly doesn't make a whole lot of sense, like laying the foundations and deciding the house looks great.

The KOL event is there to shine light on a program that's flying under the radar. Maybe it's telling investors "you're going to be thinking about investing in cancer in the coming months but you're getting this shot at a blockbuster as well for free". Maybe they think there's some value to the partnering process to having two of the leading voices in NASH drug development speaking about their program, it's not the thing that gets deals signed but it can't be a bad thing. Having gone through this long regulatory process it makes sense to go into depth on where the program stands now.

 

palinc2000 wrote: The reasons for holding the KOL event can range from no interest at all and rhus teying to prop up the SP high enough to draw on the ATM to a lot of interest but too low financial terms which again would also require to prop up the SP
In the meantime of course we know that there is no deal....

quote=SPCEO1]I hope I am wrong but I struggle to see a reason for the KOL event if there were any substantial partnership interest. Or maybe there has been some interest but it has been too low on the financial terms and the purpose of the KOL event is to show they have support from investors to go it alone in order to get better terms from the potential partners.

 

Wino115 wrote:

Maybe ask for each KOLs view on a hypothetically good partner and why?  Would be interesting to hear what aspects of the program they view as important to other players. 

 

qwerty22 wrote: Do you think if somebody asked at the KOL event if anybody was in the data
room, taking a look at the program, they would answer that? Not who, just yes/no anybody in there?

 

 


 

 




[/quote]

<< Previous
Bullboard Posts
Next >>